Archives of Clinical Infectious Diseases

Published by: Kowsar

Dalbavancin, Oritavancin and Tedizolid are Safe and Effective for Skin Infection Treatment

Masoud Mardani 1 , *
Author Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Clinical Infectious Diseases: June 30, 2014, 9 (3); e22065
  • Published Online: June 25, 2014
  • Article Type: Editorial
  • Received: April 27, 2014
  • Accepted: May 14, 2014
  • DOI: 10.5812/archcid.22065

To Cite: Mardani M. Dalbavancin, Oritavancin and Tedizolid are Safe and Effective for Skin Infection Treatment, Arch Clin Infect Dis. 2014 ; 9(3):e22065. doi: 10.5812/archcid.22065.

Copyright © 2014, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
References
  • 1. Jenkins TC, Knepper BC, Sabel AL, Sarcone EE, Long JA, Haukoos JS, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med. 2011; 171(12): 1072-9[DOI][PubMed]
  • 2. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin infect dis. 2011;
  • 3. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007; 357(4): 380-90[DOI][PubMed]
  • 4. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005; 41(10): 1407-15[DOI][PubMed]
  • 5. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014; 370(23): 2169-79[DOI][PubMed]
  • 6. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014; [DOI][PubMed]
  • 7. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010; 30(1): 80-94[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments